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The use of illicit substances has increased dramati-
cally over the last 10 years in Taiwan. The common 
drugs of abuse includes ethanol, amphetamines/
methamphetamines, heroin/morphine/opiate, meth-
adone, cocaine, marijuana, barbiturates, benzodi-
azepines and phencyclidine/ketamine.1,2 The drug 
abusers have higher risk of unprotected sexual inter-
courses and subsequent pregnancies. The influence 
of drug abuse during pregnancy has affected women 
in many domains. Consequently, fetuses and infants 
with intrauterine exposure to illicit substances may 
suffer from developmental problems and withdrawal 
symptoms.3−5
Some abused substances have been reported to 
be potential teratogens for the fetus. In the imma-
ture mammalian brain during brain growth spurts/
synaptogenesis period, the synaptic connections may 
be disrupted by abnormally suppressed neuronal 
activity and the nerve cells may receive an internal 
apoptosis signal as a result.5,6 This kind of neural ap-
optosis can be triggered by the transient blockade of 
glutamate N-methyl-d-aspartate (NMDA) receptors, 
or the excessive activation of γ-amino-butyric acid 
(GABAA) receptors.7,8 The associated apoptogenic 
agents include anticonvulsants (barbiturates, ben-
zodiazepines, phenytoin, valproate), anesthetics (ke-
tamine, nitrous oxide, propofol), and some other 
abused substances (phencyclidine, ethanol).6,9,10 
Phencyclidine (PCP, angel dust) and ketamine (spe-
cial K) are potential NMDA antagonists which induce 
apoptotic neurodegeneration in the developing rat 
brain.7 Barbiturates and benzodiazepines are GABA 
mimetics that cause neuroapoptosis in the devel-
oping rodent brain.8 Phenytoin and valproate are 
voltage-gated sodium ion channel blockers that may 
suppress neuronal activity and induce a neuroap-
optotic response similar to that of the GABA mi-
metics in the developing rat brain.5 Ethanol, with 
both NMDA antagonist and GABA mimetic properties, 
was found to have robust evidence of triggering a 
neurodegenerative response in the developing ro-
dent brain.11 A single ethanol intoxication episode 
may cause apoptosis of millions of neurons in the 
developing brain, with the most severely affected 
regions including the parietal cortex, cingulate 
cortex, and rostral hippocampus.12
Spontaneous abortion, stillbirth, fetal and infant 
growth retardation, fetal alcohol syndrome and at-
tention deficit disorder have been reported to be 
the adverse outcomes of prenatal ethanol consump-
tion.13,14 The effects of intrauterine exposure of 
heroin/methadone include delayed physical growth, 
neurologic performance and cognitive development, 
in addition to withdrawal symptoms.15 Decreased 
head circumference, hypertonia and lower cognitive 
scores have been described to associate with intrau-
terine cocaine exposure.3,16 Smaller infants with a re-
duction in gestational age and small for gestational 
age at birth have been reported to relate to intrauter-
ine phencyclidine/ketamine exposure.17,18 Therefore, 
the fetuses, infants, or children with intrauterine 
substances exposure may require early intervention 
and follow-up treatment not only for the withdrawal 
symptoms, but also for the long-term sequels.4,5
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Among the group of women with illicit drug 
abuse, the number with unplanned pregnancies has 
increased. These groups of pregnant women seldom 
admit the usage of illicit substances, or usually un-
derreport the period of usage during pregnancy. 
Because the maternal blood and urine drug tests 
are effective for recent exposure within a few days 
only, the maternal hair, meconium, and umbilical 
cord have been assessed for drug testing as means 
of detecting prenatal drug exposure.19,20 In the case 
reported by Su et al21 in this issue, neonatal hair 
and maternal hair drug tests were carried out to 
confirm the prenatal ketamine abuse successfully. 
Neonatal hair drug testing may become an alterna-
tive method for detection of intrauterine illicit drug 
exposure, with further investigation.
Substance dependence has become a major pub-
lic health problem worldwide. Different programs 
of multiple substances screening for drug abusers 
during the parturition or prenatal care visits have 
been introduced in some institutes in the United 
States, because most pregnant abusers are unwill-
ing to concede the usage and many drug abusers 
use more than one substance.22−25 A 19% screened 
positive rate detected by a universal screening pro-
gram has been reported at the University Hospital in 
New Orleans. Low birth weight and being positive for 
HIV were particularly prevalent in those with cocaine 
and/or amphetamines abuse.25 Histories of self-
reported tobacco use and ethanol use during preg-
nancy were found to be the indicators of illicit drug 
abuse.25 In addition to the potential short-term and 
long-term adverse effects on children, prenatal illicit 
drug exposure is also associated with poor maternal 
nutritional status, impaired caregiving, infectious 
diseases and domestic violence.26,27 Comprehensive 
care should be provided to the families of infants 
with detected prenatal illicit drug exposure. Early 
intervention and a better nurturing environment 
can improve the outcomes of these children, and 
the health condition of subsequent infants of the 
same mother.27,28 Therefore, prenatal or neonatal 
illicit substance screening for high-risk cases may 
be helpful for both infants and their families.
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